Form 4: ARTL Director Converts Notes to Warrants, New Note

Artelo Biosciences director Connie Matsui converted a portion of a convertible promissory note into warrants and reinvested the remainder into a new convertible note and additional warrants.

Summary

• Connie Matsui, a Director of Artelo Biosciences, Inc. (ARTL), engaged in a series of transactions involving convertible promissory notes and warrants on October 28, 2025.
• A portion of a convertible promissory note issued to Ms. Matsui on May 1, 2025 (the "May Note") was automatically converted into a warrant to purchase 38,346 shares of the Issuer's common stock (the "$6.24 Warrant") with an exercise price of $6.24.
• The remaining portion of the May Note was converted and reinvested into a new convertible note (the "October Note") with a principal amount of $110,843.
• Concurrently, the remaining portion of the May Note was also reinvested into a warrant to purchase 70,376 shares of the Issuer's common stock (the "$3.40 Warrant") with an exercise price of $3.40.
• The October Note grants Ms. Matsui the right to convert its principal amount, plus accrued and unpaid interest, into shares of the Issuer's Common Stock at any time prior to full payment.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the transactions introduce potential dilution, the director's reinvestment of capital into new convertible instruments suggests continued commitment and belief in the company's prospects. It's a restructuring of existing capital rather than a new cash raise or a sell-off.

Positives

• The reinvestment by a director demonstrates continued confidence in the company's future, as capital is being maintained within the company structure rather than being withdrawn.
• The conversion of debt (promissory notes) into equity-linked instruments (warrants and convertible notes) can reduce immediate cash outflow requirements for the company.

Negatives

• The issuance of warrants and convertible notes introduces potential future dilution for existing shareholders if these instruments are exercised or converted into common stock.
• The specific conversion prices and warrant exercise prices ($6.24 and $3.40) provide benchmarks that could influence market perception of the company's valuation.

Risks

• Potential future dilution of existing shareholders if the warrants are exercised or the October Note is converted into common stock.
• The company's stock price performance relative to the warrant exercise prices and conversion terms will impact the value realized by the reporting person and the dilutive effect on other shareholders.

Future Outlook

The reporting person has the right to convert the principal amount of the October Note, along with accrued and unpaid interest, into shares of the Issuer's Common Stock at any time prior to its full payment. The warrants are exercisable immediately and expire in 2030.

Industry Context

This transaction is a routine insider filing (Form 4) detailing changes in beneficial ownership of derivative securities. It reflects a director's individual investment decisions and the company's financing structure rather than broader industry trends. Such conversions are common in early-stage or growth companies seeking to manage their capital structure.

Related Party Transactions

• Connie Matsui, a Director of Artelo Biosciences, Inc., is the reporting person involved in these transactions, making them related party dealings.

Stakeholder Impact

• Shareholders: Potential for future dilution if the warrants are exercised or the October Note is converted into common stock, which could impact per-share value.
• Company: The restructuring of the May Note into new convertible instruments helps manage the company's capital structure and potentially defers cash repayment obligations.

Next Steps

• The reporting person may choose to convert the October Note into common stock at any time prior to its payment in full.
• The reporting person may choose to exercise the $6.24 Warrant or the $3.40 Warrant at any time prior to their respective expiration dates.

Key Dates

Recommendation

This Form 4 details an insider's conversion and reinvestment of existing debt into equity-linked instruments. While it signals continued insider confidence, it does not provide new fundamental information about the company's operations or financial performance that would warrant a strong buy or sell recommendation. The potential for future dilution is a factor, but the transaction itself is a restructuring of existing capital rather than a new cash infusion or a significant sell-off. Investors should monitor future conversions or exercises and broader company performance.

Keywords

Artelo Biosciences, ARTL, Form 4, Insider Transaction, Convertible Note, Warrant, Equity Conversion, Director Transaction, SEC Filing